Therapeutic potential of human adipose tissue-derived multi-lineage progenitor cells in liver fibrosis

Healing Effect of Conditioned Media from Bone Marrow-Derived Stem Cells in Thioacetamide-induced Liver Fibrosis of Rat

“…In liver fibrosis, there is excessive accumulation of extracellular matrix, which affects liver function over time and leads to its failure. In a mouse model of liver fibrosis, the effectiveness of human adipose tissue-derived multi-lineage progenitor cells in improving liver fibrosis was shown (Okura et al, 2014). Considering BMSCs, it was shown that injection of these cells resulted into improvement in the histological picture of the liver and its enzymatic profile (Ahmed et al, 2014).…”

Therapeutic potential of adipose tissue-derived multi-lineage progenitor cell-sheets on liver fibrosis

“…Rat ADMPCs were prepared as described previously [8][9][10]14]. Briefly, the rat inguinal adipose tissue was minced and then digested at 37°C for 1 h in Hank's balanced salt solution (HBSS, GIBCO Invitrogen, Grand Island, NY) with Liberase (Roche Diagnostics, Germany) as indicated by the manufacturer.…”

“…Recently, cell therapy has been proposed as an attractive tool for treatment of patients with severe liver fibrosis [8][9][10][11][12][13][14]. Mesenchymal stem cells, which possess certain characteristics including self-renewal, proliferation, differentiation and/or secretion of bio-active cytokines, are promising tools in cell therapy [14].…”

“…Mesenchymal stem cells, which possess certain characteristics including self-renewal, proliferation, differentiation and/or secretion of bio-active cytokines, are promising tools in cell therapy [14]. The effectiveness of bone marrow or adipose tissue-derived cells in animal models of liver fibrosis and cirrhosis have been demonstrated by several groups including us [14,[15][16][17][18][19][20]. However, others have reported the lack of any changes in the extent of liver fibrosis or liver function tests following the use of BM-MSCs in the animal models of severe chronic liver injury [21].…”

“…Major part of previous reports demonstrated their routes of administration were intravenous [14,[16][17][18][19][20]. The intravenously administered cells have reported to be accumulated to the lung and then the liver with loss of administrated cell numbers [24], resulted in reduction of efficacy.…”